Long-serving senior executive of lepu medical technology resigns, can the second generation successor stop the decline in performance? | Express announcement
①Tonight, lepu medical technology announced that General Manager Zhang Zhibin and Deputy General Manager Zheng Guorui resigned, and the Chairman's daughter Pu Fei took over as General Manager, with a "sea turtle elite" background; ②Starting from 2023, lepu medical technology's performance has declined for several consecutive quarters, and the market cap has dropped by one quarter compared to its peak period.
The threat of additional tariffs looms high, intco medical technology's stock price drops by 20%, What are the prospects for its North American layout?
①Today, Intco Medical Technology's stock fell 20 centimeters in the intraday trading session. An employee from the securities department of Intco Medical Technology stated, 'This is because the United States announced the impact of increasing tariffs on some Chinese commodities under Section 301.' ②The employee said that the proportion of the U.S. market in the company's revenue is about 35%, which may pose challenges to the company's performance in the short term. However, the overall potential of the U.S. market is still significant, and the company still plans to increase its efforts to expand into the North American market.
Tsubota Lab has signed an exclusive implementation license agreement with shenyang xingqi pharmaceutical.
On the 5th, Tobita Lab <4890> announced that they have signed a patent license agreement with China's ophthalmology drug manufacturer Shenyang Xingqi Pharmaceutical (hereinafter referred to as Xingqi) to grant exclusive rights to certain patents in specific regions.
Livzon Pharmaceutical Group Inc. expects reduced performance pressure in the second half of the year | Live coverage of the earnings conference
① At the results meeting, Yang Liang, director of Lizhu Group, responded to issues such as the year-on-year decline in the company's revenue and financial data in various segments; ② Tang Yanggang, president of the company, said that the overall market size of tocilizumab injections in China is small.
Another unreasonable suppression! The U.S. House of Representatives has passed the Biosecurity Act, and wuxi apptec and wuxi bio have quickly responded.
①The U.S. House of Representatives passed the draft of the Biosecurity Act (H.R.8333) with 306 votes in favor and 81 votes against. ②Wuxi Apptec, Wuxi Bio, and other companies strongly opposed it. ③This bill still needs to be voted on by the Senate and the versions passed by both houses need to be reconciled before it can be submitted to the U.S. President for signing into law.
chongqing zhifei biological products' 23-valent pneumonia vaccine joins the "price reduction group" just one year after its launch.
① Chongqing Zhifei Biological Products 23-valent pneumococcal polysaccharide vaccine has lowered its online price by nearly 30% in provinces such as Jiangsu and Jilin; ② Currently, China's pneumococcal vaccine market is showing a competitive situation of "wrestling" between overseas MNCs and domestic companies, and more and more companies are expanding their presence in this field; ③ Industry experts believe that in order to occupy the market, companies can only choose to actively reduce prices.